Hawaii House Bill HB2145

Hawaii 2026 Regular Session

• Introduced: 1/28/26
• Refer: 1/30/26

Caption

Relating To Insurance Coverage Of Proton Beam Therapy.

Impact

This legislation significantly impacts state health insurance laws, particularly by expanding the types of cancer treatments covered. By adding proton beam therapy to mandatory coverage, the bill aims to improve access to advanced cancer treatment methods that may be clinically necessary for patients. This aligns with a broader effort to enhance cancer care options available to residents while ensuring that insurance companies adopt fair treatment standards across different forms of radiation therapy.

Summary

House Bill 2145 pertains to the coverage of proton beam therapy for cancer treatment under health insurance policies in Hawaii. The bill mandates that all individual or group accident and health insurance policies issued or renewed in the state starting January 1, 2027, must cover medically necessary proton beam therapy when providing benefits for radiation oncology. Furthermore, the bill stipulates that insurers cannot impose stricter clinical evidence standards for proton beam therapy compared to other forms of radiation therapy treatment, ensuring equitable treatment options for cancer patients.

Contention

The bill's provision that prohibits insurance providers from applying higher standards for proton beam therapy could lead to discussions around the cost implications for insurers and the potential effects on premiums. There may be concerns from insurers about the financial sustainability of covering such specialized treatments, especially if they argue that the evidence for proton therapy is not as robust as for other radiation therapies. Additionally, while some advocacy groups may support the bill as a victory for patient rights and treatment access, others may raise issues regarding the overall healthcare costs associated with mandated treatments.

Legislative history

The bill is set to take effect on July 1, 2026, providing a timeframe for health insurers to adjust their policies and prepare for the new requirements. Supporters of the bill include healthcare advocates who emphasize the need for comprehensive cancer care, while opposition may include parties concerned about increased healthcare costs. Its passage represents a growing recognition of the importance of innovative cancer treatment options and the roles they play in patient outcomes.